Trolovol® : IMAXIO acquires Trolovol, an orphan drug indicated for a congenital metabolic disease (January 22nd, 2013)

IMAXIO & Merial : Signing of an option for a licence agrement to develop an animal health vaccine (December 17th, 2012)

Leptospirosis : Regards sur la leptospirose #1 - Une zoonose à répartition mondiale (November 14th, 2012)

Genomics: IMAXIO boosts genomics capacity with new automated equipment (June 27th, 2012)

Funding: IMAXIO closes € 2.9-million funding round (April 17th, 2012)

IMAXIO profile: Update of the company profile (February 16th, 2012)

Illumina platform: Installation of the Illumina ultra high throughput genotyping platform (February 1st, 2010)

IMAXIO & Oxford University: Collaboration agreement to develop new vaccines (October 1st, 2009)

Funding: Historical funding of € 2.75 Million (June 24th, 2009)

 IMAXIO & Cellmade: Mutualisation of the technological platforms of IMAXIO and CellMade (March 30th, 2009)

 IMAXIO & Institut de Recherche Pierre Fabre: Development of a test accompanying a new therapeutic product (January 7th, 2009)

IMAXIO & Axcell Biotechnologies: Acquisition of Axcell Biotechnologies (December 18th, 2008)

IMAXIO & CRSSA: Signature of an initial agreement (September 1st 2008)

Scientific publications: Two publications in "Infection & Immunity" and "Nature Medicine" (August 26th, 2008)

IMAXIO & Centre René Huguenin: Signature of a partnership agreement to develop a DNA chip in the field of oncology (June 25th, 2008)

IMAXIO & Centre Jean Perrin: Signature of a partnership agreement in the field of oncology (April 11th, 2007)